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Background: Safety assessment beyond the dose-limiting toxicity evaluation period provides relevant information
to define the recommended phase II dose (RP2D) of a new treatment. We retrospectively analyzed three phase I trials to
illustrate two indicators: per-cycle probability of graded toxicity and cumulative probability of severe toxicity over the
treatment period.
Patients and methods: Data were collected from two continual reassessment method (CRM) trials (T1: aviscumine in
solid tumors with short time on treatment; T2: erlotinib + radiotherapy in brainstem gliomas with longer time on treatment)
and one 3 + 3 design (T3: liposomal doxorubicin + cyclophosphamide combination in ovarian carcinoma). The probability
of severe and moderate or severe toxicity per cycle was estimated at each dose level with mixed proportional odds
model. The cumulative probability of severe toxicity was also estimated with the time-to-event CRM.
Results: Eighty-three patients were included in the three trials; 94, 96 and 72 treatment cycles were administered, in T1,
T2 and T3, respectively. Moderate toxicities were at least twice as frequent as severe toxicities. An increased probability of
toxicity over time was detected in T3 [P = 0.04; per-cycle probability of severe toxicity: 27% (cycle 1) to 59% (cycle 6) at the
RP2D]. At the RP2D, 37% of patients experienced at least one severe toxicity over the first six cycles in T2, and 78% in T3.
Conclusions: Dedicated methods can be used to analyze toxicities from all cycles of treatment. They do not delay accrual
and should be integrated in the analysis and reporting of phase I dose-finding trials.
Key words: dose-finding trials, phase I, dose-limiting toxicity, longitudinal studies, cumulative toxicity, statistical analysis
introduction
Phase I oncology clinical trials are designed to evaluate the tox-
icity profile of a new treatment and to identify a dose that can be
safely recommended for phase II trials (RP2D). Classically, the
RP2D is a dose associated with a predefined probability of severe
toxicity (grade 3, 4 or 5 according to the NCI CTC-AE scale),
often between 20% and 30%. The main end point, called dose-
limiting toxicity (DLT), is usually evaluated during the first cycle
of treatment. This period of observation is also sometimes called
‘DLT window’. Two classes of methods have been developed to
find this dose, sometimes called algorithmic designs, such as the
traditional 3 + 3 design, and model-based designs, such as contin-
ual reassessment method (CRM). Regardless of the statistical
method used, a considerable volume of the collected information
is not formally analyzed to identify the RP2D, as only severe toxi-
cities collected in the DLT window are taken into account for
dose finding.
Phase I trials provide much more information than the sole
evaluation of DLT, including the graded severity of toxicities,
as well as repeated measurements of toxicities throughout
the treatment period. In a retrospective study of 445 patients
included in phase I trials of molecularly targeted agents, more
than 50% of severe toxicities occurred after the first cycle of
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treatment. The occurrence of cumulative or late toxicities is also
feared, not only due to previous examples such as cardiac tox-
icity of anthracyclines, but also because some agents are deliv-
ered over prolonged period of time. The DLT-TARGETT
initiative led by the European Organization for Research and
Treatment of Cancer (EORTC) recommended taking into
account certain lower grades of toxicities and toxicities that occur
after the first cycle in assessment of the RP2D [1].
However, simply extending the DLT evaluation window raises,
many issues including delayed accrual and nonassessable patients
in case of early drop out for progressive disease. Furthermore, se-
lection bias due to dropouts cannot be excluded in such series, as
the majority of phase I trial participants remain on study only for
a short period of time.
Some methodological alternatives are available. The objective
of this study was to illustrate how the enriched information of the
toxicities experienced through the whole treatment period can be
rigorously analyzed to refine the RP2D, without delaying patient
accrual. Repeated measurements of toxicities have rarely been
used in this context. An extension of the CRM was recently pro-
posed to either prospectively use repeated assessments of graded
toxicity or to retrospectively reanalyze the collected data to refine
the estimate of the RP2D and to investigate modification of the
probability of toxicity over time [2]. These approaches provide
investigators with a probability of toxicity at each cycle. If this
probability increases with time, then cumulative or late effects
cannot be excluded.
Another approach, TIme-To-Event CRM (TITE-CRM), pro-
vides estimates of the cumulative probability of toxicity over
several cycles. It was proposed to address the issue of late toxici-
ties in radiotherapy dose-finding trials [3]. This method is not
based on repeated events, but on the first severe toxicity and it
cannot be used to investigate time trends.
To illustrate clinically how toxicity occurring after the first
cycle of treatment can be integrated in the final definition of the
RP2D, we retrospectively analyzed three completed phase I clin-
ical trials of anticancer agents corresponding to two situations:
two agents administered for numerous cycles of treatment and
one agent administered for few cycles. We compared the results
obtained from two analyses based on: (i) modeling of repeated
measurements of graded toxicity to identify a possible increased
probability with successive cycles and to estimate the per-cycle
probability of moderate or severe toxicity at each dose, and
(ii) estimation of the cumulative probability of severe toxicity
over the treatment period. We show the added value of these
approaches compared with using only events occurring during
the traditional DLT window.
methods
characteristics of the three trials
General characteristics of the three trials and toxicity profiles are summarized
in Supplementary Tables S1 and S2, available at Annals of Oncology online.
Aviscumine trial. The EORTC carried out a CRM phase I trial of i.v.
aviscumine, an Escherichia coli-derived recombinant type II ribosome-
inactivating protein, in patients with solid tumors [4]. Forty-one patients
were evaluated at 14 increasing doses ranging from 10 to 6400 ng/kg. Four
DLTs were observed: one grade 3 fatigue (4000 ng/kg) and three grade 3 liver
toxicities (at 4800 and 6400 ng/kg). At the end of the trial, the RP2D was
5600 ng/kg (13th dose).
ERLOTINIB trial. The European consortium Innovative Therapies for
Children with Cancer (ITCC) carried out a CRM phase I trial of erlotinib, a
tyrosine kinase inhibitor of the Epithelial Growth Factor Receptor, in
combination with radiotherapy in children with pontine glioma [5]. Twenty
children were evaluated at three increasing doses of erlotinib ranging
from 75 to 125 mg/m2. Two DLTs were observed: fatal grade 5 seizures,
grade 3 skin rash and pruritus (at the first and last dose levels, respectively).
The third level was recommended.
Caelyx®–cyclophosphamide trial. A 3 + 3 phase I dose-finding trial of
the combination of pegylated liposomal doxorubicin and cyclophosphamide
was conducted in patients with early recurrence of ovarian carcinoma [6].
Twenty-one patients were evaluated at five dose levels ranging from 35 to 45
mg/m2 for doxorubicin and 500 to 600 mg/m2 for cyclophosphamide. DLTs
were observed in two patients at the fifth level: grade 3 esophagitis with
grade 4 neutropenia and grade 3 thrombocytopenia; grade 3 stomatitis and
vomiting with constipation and asthenia. The fourth level was recommended
(doxorubicin 40 mg/m2 + cyclophosphamide 600 mg/m2).
data collected
We focused on the first six cycles of treatment and used the cycle as time
scale. All adverse events at least possibly related to treatment were collected.
To evaluate the per-cycle probabilities of severe or moderate toxicities, the
outcome of interest was the worst grade of toxicity at each cycle, recoded
as: 1 = no or grade 1 (mild) toxicity, 2 = moderate toxicity (grade 2) or 3 =
severe toxicity (grade 3–5). In all trials, the definition of DLT then approxi-
mately corresponded to the ‘severe’ toxicity outcome; severe toxicities could
be observed at all cycles.
statistical analysis
Each of the three trials was reanalyzed separately to provide: (i) per-cycle
probabilities of severe and moderate or severe toxicity, (ii) cumulative prob-
ability of severe toxicity over six cycles.
per-cycle probability of severe toxicity, and moderate or severe
toxicity. At each dose and each cycle, a percentage of patients experience
outcomes. The probability of severe toxicity and the probability of moderate
or severe toxicity can then be estimated. Both probabilities are assumed to
increase with the dose and correspond to the dose–toxicity relationships. In
addition, it can be assumed that increasing the dose has the same effect on
the probability of severe toxicity and the probability of moderate or severe
toxicity. The proportional odds model is a natural extension of the logistic
model when the outcome is an ordered categorical variable [7]. A mixed-effect
proportional odds model (POMM) was used to take into account the
correlation between repeated observations for a given patient [2]. This model is
also an efficient mean to account for missing at random data. Indeed, patients
stop treatment due to severe toxicity or progression, and outcomes that would
have occurred after a patient dropped out can be seen as missing data. Under
the assumption that (i) the risk of progression at a dose is largely independent
on the risk of toxicity, (ii) the risk of going off study for toxicity is only related
to the dose and to previously observed outcomes, maximum likelihood
estimates of mixed models provides unbiased estimates.
Let Yij be the outcome that can take values k = 1 (mild), 2 (moderate) or
3 (severe) for patient i at cycle j. Let di be the dose allocated to the patient
when (s)he is enrolled in the trial.
log
PðYij  kjdi; tijÞ
1 PðYij  kjdi;tijÞ
 
¼ ak  b1di  b2tij  ui with ui  N 0;s 20
 
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Note that β2 estimates the effect of time. No interaction between dose and
time is modeled due to the lack of power to detect interaction with phase
I sample sizes. Details are provided in supplementary Appendix A, available
at Annals of Oncology online.
cumulative probability of severe toxicity. We also investigated the
probability for a patient to experience a severe toxicity during the first six
cycles of treatment, as in the TITE-CRM [3]. The relationship between the
dose and the time to first severe toxicity was modeled by a weighted logistic
function (see details in supplementary Appendix A, available at Annals of
Oncology online). In this approach, observations of patients without severe
toxicity are down-weighted proportionally to the length of follow-up; for
instance a patient who dropped out after three cycles and who did not
experience severe toxicity was attributed a weight of 0.5. The cumulative
probability after six cycles was also represented using the Kaplan–Meier
(KM) method.
In the trial of a combination of two molecules (Caelyx®–cyclophospha-
mide, CACY), the dose of each molecule was included separately, by assum-
ing no interaction between the two molecules. In all models, 95% confidence
intervals (CIs) of the estimated probabilities were calculated by a multivari-
ate delta method. We computed a measure of the relative gain in precision of
the final estimate of the probability of severe toxicity: precision was quan-
tified as half the length of the 95% CI and gain was the relative improvement
in precision using repeated ordinal data over the precision using binary data
at the first cycle only.
results
The distributions of outcomes are presented for each trial in
terms of doses and cycles in Figure 1. The estimates for the
POMM are given in supplementary Table S3, available at Annals
of Oncology online.
aviscumine trial: a trial with short time on treatment
At the end of the trial, the estimated probability of DLT at cycle
1 was 16% (95% CI 7% to 37%) at the RP2D. Of the 97 cycles
administered to the 41 patients included, 94 cycles delivered up
until the sixth cycle were selected (mean: 2.3 cycles/patient,
Table 1). Grade 2 and 3 toxicity were the worst grades in 34 and
7 cycles respectively, including 17 grade 2 and 2 grade 3 that oc-
curred after the first cycle. Seven patients experienced at least
one severe toxicity over the six cycles.
The probability of toxicity did not vary significantly with time
(P = 0.27). As shown in Table 1, the estimated probability of
severe toxicity at each cycle at the RP2D was 13.6% (95% CI
5.8% to 27.6%), which means that, for each cycle received, the
probability of experiencing severe toxicity was 13.6%. The prob-
ability of moderate or severe toxicity was 60.6% (95% CI 42.7%
to 76.3%). The relative gain of precision obtained by analyzing
ordinal repeated data was 27% compared with the CRM on
cycle 1 and binary data only.
TITE-CRM analysis was not relevant in this trial, as all grade
3 toxicities occurred during the first two cycles.
ERLOTINIB trial: a trial with longer time
on treatment
The probability of DLT at the RP2D was 16% (95% CI 4% to
45%) according to the CRM [5]. A total of 96 cycles were deliv-
ered up to the sixth cycle in 20 children (mean: 4.8 cycles/child,
Table 1). Nineteen and 7 cycles with worst grade 2 or grade 3–5
toxicity were recorded respectively, including 4 cycles with
severe and 13 cycles with moderate toxicity outcome experi-
enced after the DLT window. Six patients experienced severe
toxicities over the six cycles.
The probability of toxicity did not vary over time (P = 0.83),
suggesting the absence of cumulative effect. The estimated per-
cycle probability of severe toxicity was 8.6% (95% CI 3.7% to
18.7%) at the highest investigated dose (Table 1). The width of
the 95% CI was strongly reduced by 63% when compared with
analysis restricted on the DLT window only. The estimated
probability of moderate or severe toxicity per cycle was 30.8%
(95% CI 18.7% to 46.3%).
Using the TITE-CRM approach, the probability for a child to
experience severe toxicity over the first six cycles was 37.2%
(95% CI 12.2% to 71.5%) at the RP2D. This estimation was very
close to the estimation obtained with the KM approach (supple-
mentary Figure S1, available at Annals of Oncology online).
CACY trial: an increased probability of toxicity with
increasing cycles
Twenty-one patients received 77 treatment cycles, including 72
cycles delivered up until the sixth cycle (mean 3.4 cycles/patient,
Table 1). The worst grade experienced at each cycle was 33
grade 2 and 18 grade 3 or 4; 9 grade 3 or 4 and 14 grade 2 toxici-
ties occurred after the DLT window. Eleven patients experienced
severe toxicities over the six cycles.
A significant time trend (β2 = 0.42, odds ratio (OR) = 1.52 per
treatment cycle, P = 0.04) was detected. The estimated probabil-
ity of severe toxicity at the RP2D increased from 27.1% (95% CI
8.8% to 56.3%) at cycle 1 to 59.2% (95% CI 25.6% to 86.7%) at
cycle 6 (supplementary Figure S2, available at Annals of
Oncology online); the probability of moderate or severe toxicity
was 72.4% at the first cycle (95% CI 44.1% to 90.5%) and 92.2%
at the sixth cycle (95% CI 66.4% to 99.9%). The gain in precision
could not be evaluated, as no confidence interval was estimated
in the 3 + 3 trial.
In the TITE-CRM analysis, the cumulative probability of
severe toxicity over six cycles was 78.2% (95% CI 41.4% to
94.8%) for the RP2D. The estimate was 67.7% (95% CI 28.5% to
85.4%) using the KM approach (supplementary Figure S1, avail-
able at Annals of Oncology online).
discussion
This retrospective analysis of three completed clinical trials illus-
trates the additional information provided by global modeling
of the severity of safety data collected at all treatment cycles in
three situations (short and longer follow-up and increased prob-
ability of toxicity with time). Moderate or severe toxicities can
be analyzed to refine estimation of the safety of the RP2D; more
than one-half of toxicities were experienced after the first cycle.
A previously unreported time effect was detected for one trial.
Two approaches were distinguished. The POMM analysis
provides estimates of the probabilities of severe and moderate
toxicity per cycle. The number of observations used was mark-
edly increased by 2-, 3- or 5-fold (in the aviscumine, CACY and
erlotinib trials, respectively), compared with analysis based on a
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single observation per patient, resulting in narrower confidence
intervals around probability estimates. With three or six patients
at each dose level, crude toxicity rates may be misleading and
may differ from the model estimates that incorporate the con-
straints of an increasing logistic relationship. In addition, mod-
erate toxicity, provided additional information to refine the
RP2D estimates and to detect a time effect. The good operating
characteristics of this method have been investigated in the stat-
istical literature [2]; however, this is the first illustration of the
recent POMM approach on real phase I trials. Alternatively, the
time-to-event approach allowed estimation of the probability for
a patient to experience at least one severe toxicity during follow-
up. These methods are more applicable and useful for the
erlotinib and CACY trials than for the aviscumine trial, where
most patients dropped out after cycle 2.
We did not consider dose modifications here; while in our
trials, only five patients had dose reduction, the DLT-TARGETT
reported that relative dose intensity was below 80% on average.
Modeling the administered dose may then be required. We also
assumed that the probability of toxicity complied with the pro-
portional odds assumption, which implies that the effects of the
dose as well as of the time are the same for severe toxicities and
for moderate or severe toxicities. It is likely that the same mech-
anism is responsible for severe and moderate toxicities, which
makes the proportional odds assumption reasonable. Would
this hypothesis not seem reasonable, then more flexible models,
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Figure 1. Distribution of the frequency of worst grade of toxicity experienced during the cycle, over the number of observations per cycle (A, left part) and dose
level (B, right part). *Total superior to the number of patients allocated to each dose, as each patient could contribute to several cycles. In the aviscumine trial, the
severity of laboratory toxicities that had worsened from baseline was recoded. Lymphocytopenia was coded as ‘moderate’ or ‘mild’ when the grade worsened by 2
or 1 point(s) from baseline, respectively; for other laboratory toxicities, grade 3 and 2 toxicities were coded as ‘moderate’ or ‘mild’ if they had worsened by 1 point
from baseline. In CACY trial, dose levels corresponded to the combination of doses of doxorubicin and cyclophosphamide, as reported in Table 1.
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Table 1. Observed and estimated probabilities of toxicity according to the dose
Aviscumine triala Aviscumine dose (ng/kg)
3200 4000 4800 5600 45/500 Total
Number of patients 4 6 10 7 5 41
Number of cycles 13 11 25 13 8 94
Number of moderate toxicities 4 4 10 5 4 34
Number of severe toxicities 0 1 2 1 2 7
Observed moderate or severe toxicity (per cycle) % 30.8 45.5 48.0 46.2 75.0 43.6
Observed severe toxicity (per cycle) % 0.0 9.1 8.0 7.7 25.0 7.4
POMM (all cycles)
P2+ (per cycle) % 40.0 46.3 53.8 60.6 66.2
95% CI (P2+) 26.8–54.6 34.4–58.6 40.2–66.9 42.7–76.3 43.8–83.5
P3 (per cycle) % 5.8 7.7 10.4 13.6 17.0
95% CI (P3) 2.0–15.1 3.1–17.0 4.6–21.2 5.8–27.6 6.6–35.5
Data summarized over six cycles
Number (N) of patients with severe toxicity (naïve incidence, %) 0 (0.0) 1 (16.7) 2 (20.0) 1 (14.3) 2 (40.0) 7 (17.1)
Erlotinib + radiotherapy trial Erlotinib dose (mg/m2)
75 100 125 Total
Number of patients 6 6 8 20
Number of cycles 26 34 36 96
Number of moderate toxicity 4 8 7 19
Number of severe toxicity 2 1 4 7
Observed moderate or severe toxicity (per cycle) % 23.1 26.5 30.6 27.1
Observed severe toxicity (per cycle) % 7.7 2.9 11.1 7.3
POMM (all cycles)
P2+ (per cycle) % 22.7 26.6 30.8
95% CI (P2+) 11.6–39.6 18.6–36.4 18.7–46.3
P3 (per cycle) % 5.8 7.1 8.6
95% CI (P3) 2.2–14.8 3.4–14.2 3.7–18.7
Data summarized over six cycles
Number of patients with severe toxicity (naïve incidence, %) 2 (33.3) 1 (16.7) 3 (37.5) 6 (30.0)
TITE model
Cumulative probability of severe toxicity 30.8 33.9 37.2
95% CI 7.5–70.9 15.8–58.3 12.2–71.5
CACY trialb Dose (doxorubicin/cyclophosphamide, mg/m2)
35/500 35/600 40/500 40/600 45/500 Total
Number of patients 3 3 3 8 4 21
Number of cycles 7 15 14 26 10 72
Number of moderate toxicity 3 4 11 13 2 33
Number of severe toxicity 1 6 1 7 3 18
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such as the continuation ratio model could be used at the cost of
extra parameters to estimate. This model is also useful to test the
proportionality assumption using likelihood ratio tests. In add-
ition, a simulation study showed that this POMM approach
increases the accuracy of RP2D identification, despite a certain
departure from this assumption [2]. Last, the assumption that
dropouts only depend on progression and severe toxicity is ar-
guable. For instance in the erlotinib and CACY trials, two
patients went off-treatment for reason other than progression or
toxicity. This is however not frequent as observed on the DLT-
TARGETT database where <5% of the patients went off-study
for other reason than toxicity or progression [1].
In POMM analysis, the repeated outcome is the worst toxicity
experienced in each cycle. It therefore mixes different types
of toxicities. For example in the erlotinib + radiotherapy trial,
some toxicities occurred rapidly after initiating treatment (e.g.
rash) while others occurred later (e.g. paronychia), but the
overall rate of toxicity remains rather constant. Indeed, as
already shown in simulations, only a strong cumulative effect
can be detected [2]. In the CACY study, the estimated an
increased probability of toxicity was of borderline significance
with an effect of OR = 1.52 per extra cycle received (P = 0.04).
The recent experience of ceritinib accelerated approval in cri-
zotinib-resistant nonsmall-cell lung cancer illustrates the im-
portance to evaluate effects of treatment after cycle 1 in phase I
[8]. At the RP2D (i.e. approved dose), 62% of the patients had
dose reduction due to toxicity; half of the time dose was reduced
after cycle 3. An analysis of this trial using POMM may have
detected the impact of these moderate and late effects and may
have led to redefine the RP2D.
As POMM and TITE-CRM analyses provide different types
of information, one approach might be more relevant in specific
clinical settings. The cumulative probability is probably the best
summary of data when severe irreversible toxicities, such as
cardiac or renal failure, are expected, or if toxic death occurs,
which is completely unacceptable regardless of the cycle of treat-
ment. Conversely, per-cycle probability of toxicity may be more
relevant for reversible and chronic toxicity such as rash, vomit-
ing, reversible liver adverse drug reactions.
In the future, we recommend that both approaches using all
the collected data should be considered at key time-points of
dose-finding trials: when interim analysis is carried out for a
data safety monitoring board, to select a dose for an expansion
cohort, or to complete the final analysis of the trial, in order to
refine the estimates of the toxicity probabilities of the RP2D.
In conclusion, dedicated methods allow rigorous analysis of
adverse drug reactions occurring during all cycles of treatment
to evaluate the per-cycle probability of severe or moderate tox-
icity, and the cumulative probability of toxicity. These analytical
strategies should not require interruption of inclusions, do not
increase trial duration and may even contribute to shortening
trial duration. These complementary approaches should be inte-
grated in the analysis of phase I dose-finding trials, when
patients receive several cycles of treatment.
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Cytokine profile determined by data-mining analysis set
into clusters of non-small-cell lung cancer patients
according to prognosis
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Background: Immunoregulatory cytokines may play a fundamental role in tumor growth and metastases. Their effects
are mediated through complex regulatory networks. Human cytokine profiles could define patient subgroups and repre-
sent new potential biomarkers. The aim of this study was to associate a cytokine profile obtained through data mining
with the clinical characteristics of patients with advanced non-small-cell lung cancer (NSCLC).
Patients and methods:We conducted a prospective study of the plasma levels of 14 immunoregulatory cytokines by
ELISA and a cytometric bead array assay in 110 NSCLC patients before chemotherapy and 25 control subjects. Cytokine
levels and data-mining profiles were associated with clinical, quality of life and pathological outcomes.
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